Anna Konysheva

Dr. Anna Konysheva

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2026 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
AKAnna Konysheva
Anna Konysheva
SMStanislav Myasoyedov
Stanislav Myasoyedov
Background: Nausea and vomiting are prevalent symptoms in incurable patients with gastrointestinal (GI) tumors. While standard antiemetic protocols are widely used, evidence supporting mechanism-based treatment selection in palliative patients remains limited. This study compared outcomes of individualized, mechanism-based antiemetic therapy with standard treatment in this population. Methods: A prospective observational cohort study was conducted at the Palliative Medicine Department of Kyiv City Clinical Oncological Center (2022– 2024). In this non-randomized design, treatment was allocated by the treating physician based on clinical judgment of the predominant pathophysiological mechanism. One hundred patients with incurable GI tumors and nausea received standard therapy (metoclopramide plus dexamethasone; n=41) or individualized therapy: ondansetron plus dexamethasone for hepatic-related nausea, or chlorpromazine plus dexamethasone for neurogenic vomiting (n=59). The primary outcome was clinical improvement (≥ 50% reduction in Visual Analog Scale [VAS] score or vomiting frequency) at day 7. Results: Baseline characteristics were largely comparable between groups (VAS: 7.7± 0.9 vs 7.6± 0.8, p=0.747; ECOG: 3.8± 0.4 vs 3.8± 0.4, p=0.635), although hepatic metastases were more prevalent in the individualized group (78.0% vs 51.2%, p=0.005), reflecting mechanism-based allocation. Overall improvement rates were 75.6% (standard) and 88.1% (individualized) (p=0.171). In the neurogenic subgroup, chlorpromazine achieved significantly higher improvement rates than metoclopramide (100% [13/13] vs 55.0% [11/20]; Fisher’s exact test, p=0.005), with lower post-treatment VAS scores (4.2± 0.6 vs 5.5± 0.8; p< 0.001). Adverse events were not systematically assessed; however, no treatment discontinuations due to adverse effects were recorded. Conclusion: While overall improvement rates were comparable, chlorpromazine was associated with higher improvement rates than metoclopramide in the neurogenic subgroup. Given the observational, non-randomized design and the small subgroup, these findings are hypothesis-generating and require confirmation in adequately powered randomized controlled trials. They suggest that pathophysiology-guided antiemetic selection, particularly for neurogenic symptoms, warrants further evaluation in palliative GI cancer patients.

31 May 2024 in Family medicine. European practices
Verified
Journal Article
Open access
PDF file
RMRaisa Moiseenko
Raisa Moiseenko
OKOleksii Kalachov
Oleksii Kalachov
PGProkip Gordiichuk
Prokip Gordiichuk
AKAndrii Kondratenko
Andrii Kondratenko
AKAnna Konysheva
Anna Konysheva
АСАнастасія Самусєва
Анастасія Самусєва
The city of Kyiv is characterized by a high level (258.6 cases per 100,000 population) of cancer incidence and mortality. The objective: to determine the problem and prospects of providing inpatient oncology care based on the experience of the department of the Kyiv City Clinical Oncology Center (KCCOC). Materials and methods. A retrospective analysis of the work of the palliative care department of communal non-commercial enterprise “KCCOC” for 2001–2023 was carried out. The center includes a 25-bed hospital and mobile palliative care teams. A multidisciplinary approach was the basis of providing palliative care to an incurable cancer patient. Results. During this period 9,164 cancer patients in the terminal stage with high mortality rate (81.04%) received inpatient care. The average duration of stay in the hospital was 17.7 bed-days. Approximately 6% of patients readmit to the department, some of them – 3-4 times. Approximately 94% of hospitalized patients had a pain syndrome, 86% of patients received opioid analgesia. During this period, mobile palliative care teams registered and served 3,124 cancer patients, among whom 62% of patients were transferred after inpatient treatment, more than 5,700 primary visits were made. The clinical route of the palliative patient was developed and improved, which made it possible to optimize palliative care for a seriously ill oncological patient. The peculiarities of providing palliative care to incurable oncological patients in the conditions of martial law have been determined. Conclusions. Comprehensive palliative care should be a unified system of mobile and stationary care, which will make possible to control the somatic condition of the palliative patient, correct the symptoms of the disease, provide long-term support to the patient at home, which is economically feasible, allows to provide care to a larger number of patients and hospitalize in time if it is necessary. The creation of an extensive system of mobile palliative care is promising in improvement of palliative care for oncology patients (it will reduce the burden on general somatic hospitals and inpatient palliative departments), as well as qualitatively improve the provision of palliative care to patients in the primary care network.

1 June 2026 in JCO Global Oncology
Verified
Journal Article
Closed access
AKAnna Konysheva
Anna Konysheva
SMStanislav Myasoyedov
Stanislav Myasoyedov
PURPOSE: To evaluate pain syndrome characteristics, analgesic effectiveness, opioid-related adverse events, and predictors of therapy escalation in incurable patients with GI malignancies in a resource-limited, conflict-affected setting. MATERIALS AND METHODS: A retrospective analysis of medical records of 80 incurable patients with GI tumors (colon 33.8%, pancreas 23.8%, stomach 22.5%, rectum 12.5%, liver/biliary 7.5%) treated at the Palliative Care Department of the Kyiv City Clinical Oncology Center during the period of the Russian military invasion of Ukraine (2022-2024) was performed. Pain intensity was assessed using the Verbal Rating Scale (VRS). The analgesic therapy structure, escalation needs, transition trajectories, and opioid-related adverse events were analyzed. None of the patients received concurrent oncologic treatment. RESULTS: The highest pain intensity was observed in pancreatic cancer (VRS 2.68 ± 0.82), where 83.3% of patients required opioid therapy from the first day of hospitalization. Therapy escalation was needed in 23.8% of patients, most frequently with initial tramadol therapy (42.3%). Parenteral morphine demonstrated the highest effectiveness (0% escalation rate). Among nonpancreatic localizations, rectal cancer showed the highest escalation rate (40.0%) despite the lowest initial pain intensity, potentially indicating underestimated neuropathic components. Among 57 opioid-treated patients, constipation occurred in 87.7%, sedation in 43.9%, and nausea in 21.1%; all adverse events were managed with locally available medications, and no patient required opioid discontinuation. CONCLUSION: Tumor localization determines pain intensity and analgesic strategy. Parenteral morphine provides superior pain control, and opioid-related adverse events can be effectively managed with affordable, locally available medications. These institutional observations suggest that effective opioid-based analgesia is feasible in conflict-affected, resource-constrained settings and may inform pain management approaches in other environments with disrupted health care infrastructure.

10 April 2026 in Likars'ka Sprava
Verified
Journal Article
Closed access
AKAnna Konysheva
Anna Konysheva
СМС. Д. Мясоєдов
С. Д. Мясоєдов
Мета дослідження. Вивчити структуру симптоматичного навантаження у пацієнтів з інкурабельними злоякісними новоутвореннями органів шлунково-кишкового тракту (ШКТ) на етапі паліативної допомоги. Матеріали та методи. Pетроспективний аналіз медичної документації 123 пацієнтів з метастатичним раком органів ШКТ, які перебували на лікуванні у відділенні паліативної допомоги КНП "Київський міський клінічний онкологічний центр" у 2022–2025 роках. Оцінка частоти та структури симптомів, їх залежності від локалізації первинної пухлини та метастазів. Результати. Середній вік пацієнтів становив 71,1 ± 10,4 року, співвідношення чоловіків та жінок – 52% та 48% відповідно. Найчастіше діагностували рак товстої кишки (39,0%), підшлункової залози (22,0%) та шлунка (17,1%). Канцероматоз очеревини виявлено у 100% хворих, метастази в печінку – у 63,4%. Больовий синдром спостерігали у 100% пацієнтів, загальну слабкість – у 99,2%, нудоту – у 85,4%, блювання – у 68,3%, асцит – у 67,5%. Середня кількість симптомів на одного пацієнта становила 4,3 ± 1,0. Встановлено залежність частоти окремих симптомів від локалізації первинної пухлини: кишкова непрохідність частіше виникала при раку товстої кишки (19%), асцит рідше – при раку прямої кишки (35%). Висновки. Пацієнти з метастатичним раком органів ШКТ характеризуються високим симптоматичним навантаженням із середньою кількістю 4–5 симптомів одночасно. Структура симптомів залежить від локалізації первинної пухлини, що необхідно враховувати при плануванні симптоматичної терапії.